欧洲的研究表明:HLA-DQA1*05等位基因携带CD患者抗TNF药物治疗抗药物抗体发生率、继发失应答率和停药率显著增加,是首个已证实与抗TNF抗抗体产生及失应答相关的基因。约35~40%欧洲IBD患者携带HLA-DQA1*05等位基因。 来自中山六院的数据(n=345)首次在...
Factors independently associated with time to anti-TNF therapy failure included carriage of HLA-DQA1*05 allele (hazard ratio [HR], 1.2, P = .02; female gender HR, 1.6, P < .001; UC phenotype HR, 1.4, P = .009; and anti-TNF therapy type [infliximab], HR, 1.5, P = .002). The...
Carriage of HLA-DQA1*05 is thought to increase the formation of anti-tumour necrosis factor alpha (TNF-伪) antibodies, reducing the drug efficacy in Crohn's disease (CD) patients. However, little data are currently available for small-bowel Crohn's disease (SB-CD). A specific assessment of...
NUCLEOTIDE sequencingAMINO acidsALLELESA single nucleotide substitution in the exon 3 gives rise to the novel HLA‐DQA1*05:73 allele.HLA: Immune Response GeneticsGil‐Etayo, Francisco JavierArroyo‐Sánchez, DanielNio Ramírez, Jairo EduardoTerradillos‐Sánchez, PilarTejeda Velarde, Ama...
rates of immunogenicity, 92% at 1 year, were observed in patients treated with infliximab monotherapy who carried HLA-DQA1*05; conversely the lowest rates of immunogenicity, 10% at 1 year, were observed in patients treated with adalimumab combination therapy who did not carry HLA-DQA1*05. We...
分布频率均显著高于对照组,OR值均1;HLA-DQA1*0201等位基因分布频率则明显低于对照组,OR值均1.而非自身免疫性的SG患者的HLA-DQA1*0301,HLA-DQA1*0501,DQA1*0201与对照组之间无显著性差异.结论携带HLA-DQA1*0301,HLA-DQA1*0501等位基因的个体与GD患者和HT患者的发病易感性有相关性,而携带DQA1*0201等位基因的个体...
In our real-life cohort of IBD patients treated with antiTNF-a, being an HLA-DQA1*05 carrier did not act as a predictor of loss of response, either primary or secondary. The safety of anti-TNF treatment has also not been influenced by the variant. However patients HLA-DQA1*05 positive ...
Conclusions HLADQA1*05 is independently associated with a high risk of infliximab antibody formation in addition to infliximab loss of response and treatment discontinuation. There may be a role for genotype‐guided application of combination therapy in IBD.Aze Wilson...
Carriage of HLA-DQA1*05:05 and HLA-DRB1*01:02 was associated with patients who experienced consistently low adalimumab trough concentrations (HLA-DQA1*05:05: odds ratio [OR] 1.98, p = 0.0049; HLA DRB1*01:02: OR 7.06, p = 7.44E-05). CONCLUSIONS. We found a signif...
doi:10.1111/tan.14941HLAnew allelesnext-generation sequencingstop codonThe DQA1*05:01:11 allele shows the TAA (UAA) stop codon instead of the common DQA1 TGA (UGA) stop codon.Luis A. Marin RubioJesús OntaonTissue Antigens